NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Quidel's molecular diagnostic assay for detecting Clostridium difficile infections for sale in the US, the San Diego-based company said today.

Quidel said the AmpliVue C. difficile test combines isothermal helicase dependent amplification with the company's lateral flow technology in a hand-held assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.